The prostate health index (PHI) is a blood test that more accurately assesses the risk of prostate cancer than a traditional PSA test. The PHI combines three different PSA tests to create one risk ...
The ArteraAI Prostate Test uses AI to analyze biopsy images, predicting hormone therapy benefits for prostate cancer patients. Approved in the US and UK, the test aids early diagnostic decisions, ...
Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...
The need for simple, non-invasive biomarkers for prostate cancer (PCa) diagnosis is increasing. Urinary PSA (uPSA) and Zinc (uZinc) are emerging as potential PCa risk indicators. This study aimed to ...
The Prostatype® Test evaluates expression levels of three stem cell genes (IGFBP3, F3, and VGLL3), which are combined with PSA, stage, and grade to calculate P-score. Previous research found P-score ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results